Share on StockTwits
 

Equities researchers at Jefferies Group upped their target price on shares of Questcor Pharmaceuticals (NASDAQ:QCOR) from $76.00 to $89.00 in a research report issued on Wednesday, AR Network reports. Jefferies Group’s price target indicates a potential upside of 13.16% from the stock’s previous close.

In other Questcor Pharmaceuticals news, Director Broadwood Partners Lp sold 83,600 shares of the company’s stock on the open market in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $79.59, for a total value of $6,653,724.00. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Questcor Pharmaceuticals (NASDAQ:QCOR) traded down 5.65% during mid-day trading on Wednesday, hitting $74.21. 5,097,813 shares of the company’s stock traded hands. Questcor Pharmaceuticals has a 52-week low of $26.80 and a 52-week high of $80.25. The stock has a 50-day moving average of $64.99 and a 200-day moving average of $61.81. The company has a market cap of $4.370 billion and a price-to-earnings ratio of 18.06. Questcor Pharmaceuticals also was the target of unusually large options trading on Tuesday. Stock traders acquired 11,353 put options on the company. This represents an increase of 377% compared to the typical volume of 2,380 put options.

Questcor Pharmaceuticals (NASDAQ:QCOR) last posted its quarterly earnings results on Tuesday, February 25th. The company reported $1.67 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.66 by $0.01. The company had revenue of $243.00 million for the quarter, compared to the consensus estimate of $244.15 million. Analysts expect that Questcor Pharmaceuticals will post $6.73 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which is scheduled for Friday, April 25th. Investors of record on Friday, April 18th will be given a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a yield of 1.53%. The ex-dividend date of this dividend is Tuesday, April 15th.

Separately, analysts at Zacks reiterated a “neutral” rating on shares of Questcor Pharmaceuticals in a research note on Friday, January 24th. They now have a $68.00 price target on the stock. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $84.11.

Questcor Pharmaceuticals, Inc (NASDAQ:QCOR) is a biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.